Skip to main navigationSkip to main content
The University of Southampton
We're launching a new website soon and would love your feedback. See the new design
Southampton Clinical Trials Unit

AURORA

Title

Atezolizumab in patients with urinary tract squamous cell carcinoma: a single arm, open label, multicentre, phase II clinical trial.

Description

AURORA is a phase II open label trial of Atezolizumab in patients with urinary tract squamous cell carcinoma (UTSCC). UTSCC is the most common of the rare urinary tract cancer histologies, comprising 2.1–6.7% of urinary tract cancers overall. There are few data available to guide treatment decisions for UTSCC. The AURORA trial will test the hypothesis that PD-L1 inhibition with atezolizumab immunotherapy is clinically effective, tolerable and safe, in patients with urinary tract squamous cell carcinoma (UTSCC). Translational endpoints will aim to determine characteristics for responsiveness to this treatment. AURORA was developed on behalf of the International Rare Cancers Initiative (IRCI) and the National Cancer Research Institute Bladder and Renal Group.

Outcomes

Primary Outcomes:

  • To determine the clinical activity of atezolizumab in patients with incurable histologically confirmed, immunotherapy naïve UTSCC.
  • Primary endpoint: Best overall objective response rate (ORR; the percentage with partial (PR) or complete (CR) response) by RECIST v1.1

Secondary Outcomes:

  • To determine the safety and tolerability of atezolizumab in this clinical setting.
  • To determine the overall survival (OS) of patients treated with atezolizumab in this clinical setting.
  • To determine the progression-free survival (PFS) of patients treated with atezolizumab in this clinical setting.
  • To determine the duration of response of patients treated with atezolizumab in this clinical setting.
  • To determine efficacy by iRECIST as an alternative means of response assessment in this clinical setting.
  • To determine tumour volume changes of individual patients treated with atezolizumab in this clinical setting.
  • To determine the impact on quality of life of the atezolizumab in this clinical setting.
  • To determine the impact of PD-L1 expression status on clinical response.
AURORA trial design
AURORA trial design

Trial Design

AURORA is a single arm, open label, multicentre, phase II clinical trial of atezolizumab immunotherapy, in immunotherapy naive patients with urinary tract squamous cell carcinoma (UTSCC).

Recruitment is intended to occur over approximately 2 years and will follow a two stage statistical design. However, the intention to allow continuous recruitment between Stage 1 and Stage 2.

Following a Screening Phase of up to 28 days, eligible patients will be registered and will then commence atezolizumab immunotherapy, every 28 days, within a Treatment Phase of up to 1 year. On treatment discontinuation, patients will be reviewed in an End of Treatment Visit, and then 12 weekly from the end of treatment until disease progression. Following disease progression, patients will revert to routine local follow up processes.

Trial Status:

In set-up

Population:

33-36 patients aged ≥18 years with incurable histologically confirmed, immunotherapy naïve urinary tract squamous cell carcinoma.

 

CRUK logo

This trial is funded by Cancer Research UK (award reference no. CRCPJT\100018)

Senior Trial Manager:

Sarah-Jane Bibby

Trial Manager:

Kathryn Clark

Trial Coordinator:

Ben Lindfield

Data Manager:

Charlotte Stuart

 

Contact Information for trial queries:

Email: aurora@soton.ac.uk

SAE Reporting:

Email: ctu@soton.ac.uk

 

Investigator Site Files

00 AURORA Investigator Site File Index v1 18-MAR-2022

2.1 AURORA Master Patient List v1 15-FEB-2022

2.2 AURORA Screening Log v1 17-FEB-2022

3.1 AURORA Site Delegation Log v1 15-FEB-2022

3.3 AURORA Site Training Log Template v1 15-FEB-2022

4.1 AURORA Protocol v2 03-MAY-2022

4.3 AURORA Patient Information Sheet v2 28-APR-2022

4.4 AURORA Informed Consent Form v2 28-APR-2022

4.5 AURORA GP Letter v1 26-NOV-2021

5.1 AURORA Instructions for Adverse and Serious Adverse Event Reporting v1 15-FEB-2022

5.2 AURORA SAE Report Form v1 15-FEB-2022

6.1 RO5541267 Atezolizumab - IB Version 17 - September 2020

6.3 AURORA Atezolizumab 840mg Accountability Log v1 15-FEB-2022

6.4 AURORA Atezolizumab Dispensing Log v1 15-FEB-2022

8.5 AURORA Lab Manual v1 29-MAR-2022

9.1 AURORA REC Further Information Favourable Opinion Letter_24.05.2022 20220524T142639.977 GMT_HRA-I

9.1 AURORA IRASForm

10.1 AURORA Letter_of_HRA_Approval_25.05.2022 20220525T151345.343 GMT_HRA-IRAS-WORK R-1583

12.1 AURORA CTA Acceptance of Amended Request 20220524T142640.385 GMT_HRA-IRAS-WORK P-1004493

13.1 AURORA_eCRF Completion Guidelines_v2_20May2022

14.2 AURORA Site Visit Log v1 15-FEB-2022

 

Pharmacy Files

0. AURORA Pharmacy File Index v1 18-MAR-2022

3.1 AURORA Site Delegation Log v1 15-FEB-2022

3.3 AURORA Site Training Log Template v1 15-FEB-2022

4.1 AURORA Protocol v2 03-MAY-2022

4.2 AURORA Pharmacy Manual v1 17-MAR-2022

5.1 AURORA RO5541267 Atezolizumab - IB Version 17 - September 2020

5.2 AURORA Atezolizumab 840mg Accountability Log v1 15-FEB-2022

5.3 AURORA Atezolizumab Dispensing Log v1 15-FEB-2022

5.12 AURORA Unblinding Reports Note to File v1 25-MAR-2022

6.1 22.LO.0272_1004493_Letter_of_HRA_Approval_25.05.2022 20220525T151345.343 GMT_HRA-IRAS-WORK R-1583

8.1 22.LO.0272_1004493_REC Further Information Favourable Opinion Letter_24.05.2022 20220524T142639.977 GMT_HRA-I

8.1 IRASForm

9.1 CTA Acceptance of Amended Request 20220524T142640.385 GMT_HRA-IRAS-WORK P-1004493

10.2 AURORA Site Visit Log v1 15-FEB-2022

Press releases, video clips and other external websites:

(University of Southampton cannot accept responsibility for external websites)

 

Watch a video on the AURORA trial:

 

AURORA trial funding, November 2021

Privacy Settings